“In the first quarter, we made continued progress toward our upcoming Phase 2 AMPLIFY-7P event-driven interim analysis, expected next quarter-a key milestone for Elicio and for patients facing pancreatic ductal adenocarcinoma,” said Robert Connelly, CEO of Elicio. “We believe ELI-002 represents a potentially transformative approach in the treatment of mKRAS-driven tumors, and the upcoming randomized interim data readout in PDAC will be a critical validating opportunity for our AMP platform. To this end, we believe the upcoming results could demonstrate ELI-002’s impact not only in PDAC-a particularly difficult-to-treat cancer with a 5-year survival rate of 13%-but also provide momentum for broader application of our technology across additional indications. Importantly, our current cash runway extends into the fourth quarter of 2025, beyond the anticipated AMPLIFY-7P Phase 2 interim analysis.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELTX:
- Seven new option listings and one option delisting on April 16th
- Elicio Therapeutics: Buy Rating Backed by Financial Stability and Promising ELI-002 7P Developments
- Elicio Therapeutics Advances Cancer Immunotherapy Pipeline
- Elicio Therapeutics reports FY24 EPS ($4.25) vs ($6.96) last year
- ELTX Earnings this Week: How Will it Perform?
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue